Article Sidebar
Published:
Sep 6, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
A meta-analysis of the efficacy of combining diquafosol tetrasodium with conventional therapy for dry eye disease
Abstract
Purpose: To evaluate the safety and effectiveness of combining 3 % diquafosol tetrasodium (DQS) with conventional treatment in addressing dry eye disease (DED).
Methods: A comprehensive search was conducted in databases, including CNKI, VIP, WANFANG, CBM, DUXIU, PubMed, Embase, Cochrane, Web of Science, Ovid MEDLINE, Scopus, and ProQuest up to June 5, 2023. Thirteen relevant randomized controlled trials (RCTs) were included in the analysis. Odds ratios (ORs) were used for binary categorical variables, and standardized mean difference (SMD) was employed for continuous variables and presented with 95 % confidence intervals (CI). Publication bias was assessed using funnel plot diagrams and the Egger test.
Results: Combined treatment with 3 % DQS had significantly better efficacy than control group (that received conventional treatment alone) in improving clinical efficacy, prolonging tear film break-up time, increasing tear secretion volume, and reducing corneal fluorescent staining (p < 0.05). Furthermore, the treatment demonstrated a favorable safety profile.
Conclusion: In the management of dry eye disease, the inclusion of 3 % DQS displays better therapeutic effects and safety when compared to other alternative approaches. This study underscores the potential of DQS as a promising intervention for addressing the complex pathogenesis of DED. However, its long-term effectiveness and safety still need to be further evaluated.
